Company intelligence / Profile preview

InflamaCORE

Ownership: Private
Development stage: Phase 2

Overview

The company has developed novel inhibitors that block assembly of different types of inflammasomes and inhibit extracellular inflammatory processes. They have received a fast-track STTR grant from NIH to develop a biologic to treat central nervous system injury.

Therapeutic areas: ImmunologyNeurology
Modalities: Biologics
Industry: Biotech

Drug pipeline

2 assets

VAR 200

Phase 2

Indications: Focal segmental glomerulosclerosis, Alport syndrome, Diabetic kidney disease

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on InflamaCORE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InflamaCORE.

Explore the full profile